| Biological insights from 108 schizophrenia-associated genetic loci C Pantelis, GN Papadimitriou, S Papiol, E Parkhomenko, MT Pato, ... Nature 511 (7510), 421-427, 2014 | 7375 | 2014 |
| Schizophrenia risk from complex variation of complement component 4 A Sekar, AR Bialas, H De Rivera, A Davis, TR Hammond, N Kamitaki, ... Nature 530 (7589), 177-183, 2016 | 2334 | 2016 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1839* | 2021 |
| Modeling linkage disequilibrium increases accuracy of polygenic risk scores BJ Vilhjálmsson, J Yang, HK Finucane, A Gusev, S Lindström, S Ripke, ... The american journal of human genetics 97 (4), 576-592, 2015 | 1305 | 2015 |
| Mapping genomic loci implicates genes and synaptic biology in schizophrenia V Trubetskoy, AF Pardiñas, T Qi, G Panagiotaropoulou, S Awasthi, ... Nature 604 (7906), 502-508, 2022 | 1118 | 2022 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 718 | 2021 |
| Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases A Gusev, SH Lee, G Trynka, H Finucane, BJ Vilhjálmsson, H Xu, C Zang, ... The American Journal of Human Genetics 95 (5), 535-552, 2014 | 644 | 2014 |
| Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes DM Ruderfer, S Ripke, A McQuillin, J Boocock, EA Stahl, JMW Pavlides, ... Cell 173 (7), 1705-1715. e16, 2018 | 505 | 2018 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 442* | 2021 |
| Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study D Hough, S Gopal, U Vijapurkar, P Lim, M Morozova, M Eerdekens Schizophrenia research 116 (2-3), 107-117, 2010 | 315 | 2010 |
| A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia GJ Pandina, JP Lindenmayer, J Lull, P Lim, S Gopal, V Herben, ... Journal of clinical psychopharmacology 30 (3), 235-244, 2010 | 273 | 2010 |
| Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept B Franke, JL Stein, S Ripke, V Anttila, DP Hibar, KJE Van Hulzen, ... Nature neuroscience 19 (3), 420-431, 2016 | 237 | 2016 |
| Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial J Berwaerts, Y Liu, S Gopal, I Nuamah, H Xu, A Savitz, D Coppola, ... JAMA psychiatry 72 (8), 830-839, 2015 | 236 | 2015 |
| Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study S Gopal, DW Hough, H Xu, JM Lull, C Gassmann-Mayer, BM Remmerie, ... International clinical psychopharmacology 25 (5), 247-256, 2010 | 197 | 2010 |
| Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study AJ Savitz, H Xu, S Gopal, I Nuamah, P Ravenstijn, A Janik, A Schotte, ... International Journal of Neuropsychopharmacology 19 (7), pyw018, 2016 | 195 | 2016 |
| A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia G Pandina, R Lane, S Gopal, C Gassmann-Mayer, D Hough, B Remmerie, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 35 (1), 218-226, 2011 | 195 | 2011 |
| Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ... Jama 326 (17), 1690-1702, 2021 | 190 | 2021 |
| A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia HA Nasrallah, S Gopal, C Gassmann-Mayer, JA Quiroz, P Lim, ... Neuropsychopharmacology 35 (10), 2072-2082, 2010 | 181 | 2010 |
| Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia D Hough, JP Lindenmayer, S Gopal, R Melkote, P Lim, V Herben, E Yuen, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 33 (6), 1022-1031, 2009 | 153 | 2009 |
| Effect of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal vs standard care ventilation on 90-day mortality in patients with acute hypoxemic … JJ McNamee, MA Gillies, NA Barrett, GD Perkins, W Tunnicliffe, D Young, ... Jama 326 (11), 1013-1023, 2021 | 142 | 2021 |
David Hough, MDNeuroscience Drug Development ConsultantVerified email at freedombio.co
